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A B S T R A C T
Cytological diagnosis of atypical cells of cervix uteri by the Papanicolaou method was introduced in the Czech Repub-
lic (CR) very early – in 1947. The first data on the incidence of cervical cancer in CR are available from 1960 when the
rate was 32.3 cases/105 women. In 1966 the Czech National Health Law was passed that guaranteed women a yearly pre-
ventive examination by a gynaecologist including screening for cervical carcinoma that would be covered by the compul-
sory health insurance. Notwithstanding high frequency of screening visits and the fact that all women are eligible, the
incidence of CC has not changed in the last 34 years. The reasons for this include the coverage of Czech women, which is
estimated to be low (50% at the most), and that none of the cytology laboratories are accredited for screening, there are no
national registries for any aspect of screening and there are no mechanisms for evaluation of the screening process. As a
result, it is likely that the majority of cervical screening activity that is undertaken is ineffective and the implementation
of an organised and quality controlled screening programme, in compliance with the recommendations of many Euro-
pean Institutions, is urgently required to ensure that Czech women are properly protected against this disease and that
scarce healthcare resources are used in the most cost-effective manner.
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Introduction
Cervical cancer prevention in the Czech Republic
(CR) had a very auspicious start. Cytological diagnosis of
atypical cells of cervix uteri by the Papanicolaou (Pap)
method was introduced very early – in 1947 – and by
1954, Herold and Luksch had already published the man-
ual, »Cytodiagnostics of cancer of female genitals«, in the
Czech language1. In 1960, cytological consultation cen-
tres were established and these resulted in a drop in inci-
dence 32.3 cases/105 women to 27.2 cases/105 women by
1965. Then, in 1966 the Czech National Health Law was
passed which guaranteed women a yearly preventive ex-
amination by a gynaecologist, which included a Pap test
and the incidence of cervical cancer decreased again,
from 28.8 in 1966 to 21.9 in 1983. A further decline in in-
cidence from 21.9 to 20.7 in the period of 1984–90 can be
attributed to the establishment of a system of Centres of
Gynaecology–Oncology Prevention. However, since 1990,
no further decreases in the incidence of cervical cancer
have been observed (Figure 1)2.
Guidelines
In 1999, a committee of experts including gynaecolo-
gists, pathologists, cytologists and virologists prepared
the first Guidelines for the management of patients with
lesions of cervix uteri, which also included suggestions
for algorithms for primary screening. However, these
guidelines were never introduced into routine clinical
practice. Subsequently, the Ministry of Health has on
three occasion’s convened committees for screening for
cervical carcinoma with the first two of these cancelled
shortly after their establishment. Then, in July 2004, the
third committee published recommendations that in-
cluded a 1-year screening interval with classical cytology
as the primary screening test and HPV detection for the
triage of borderline findings up to 4% of the amount of
Pap smears for each laboratory. The recommended age
range is 25–60 and the insurance companies should send
invitation to women. If woman does not respond, the in-
vitation should be repeated after 2 years. The basic re-
quirement for cytological laboratory to be able to apply
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for accreditation is a minimum amount of 15,000 cervical
smears per year. Originally, the start of the screening was
expected in July 2006, but it has not yet begun.
The Current Situation
In 2003, there were 1,007 new cases of cervical carci-
noma and 398 women died from this disease in the CR2.
The highest incidence of cervical cancer occurs in the
45–49-age category (Table 1). In the age category of
15–34 years the death rate is low – 3.3%, but it is very
high in the category of 35–59 – 38.4%. These numbers
are smaller in the age category of 60–74 – 28.9% as well
as in the category of 75+ years of age – 29.4%.
The Czech National Health Law from 1966 is still
valid and it is the basis for screening in CR today where
all women (no age is specified) are entitled to a free pre-
ventive gynaecological examination once per year. This
preventive visit includes basic colposcopy and a Pap test.
All gynaecologists can perform basic colposcopy in their
office and it is paid for by the compulsory health insur-
ance ( 1.7). Only those specialists who are certified per-
form expert colposcopy and it is more expensive ( 10).
To become certified, a gynaecologist has to prove that he
diagnoses ³50 high-grade lesions annually and he has to
pass an exam in one of two accredited colposcopy centres
in CR. Altogether, there are about 2,000 private gynae-
cologists in the CR who provide this service.
For the cytological analyses of cervical smears in the
CR, there are about 50 laboratories but only three of
these process ³50,000 slides per year as recommended by
the European guidelines3 and only about half of them
that process ³15,000 slides per year as required by the
new recommendations of the screening committee of the
Ministry of Health of the CR4. For the evaluation of cyto-
logical slides the 2001 Bethesda system5 is used. Mortal-
ity and incidence data are available from the National
cancer registry which was established in 1976 and since
1991 is a member of the International Association of
Cancer Registries (IACR).
In the CR, there are 5,2 million women in total and
2.9 million women in the screening age (25–65 years of
age). The Institute of statistics and health information
reported more than 2.9 million preventive visits to gy-
naecologists in 2005 but as the identification number of
the women is not recorded, these data are of limited
value because it is impossible to distinguish repeat visits
from new visits or in any way relate the number of visits
to the number of women in the target population. In-
deed, there are no data sources concerning screening cov-
erage, but it is estimated to be 30–50%.
























































Fig. 1. Incidence and mortality of cervical cancer
in the Czech Republic2.
TABLE 1
INCIDENCE AND MORTALITY FOR CERVICAL CANCER (C53) BY AGE GROUPS IN THE CZECH REPUBLIC IN 20032
Total
Age group
15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
New cases 1007 1 7 38 70 105 110 124 115 132 73 62 60 55 34 21
Incidence* 19.2 0.3 1.9 8.5 19.2 30.8 34.9 33.2 28.7 34.8 25.8 27.0 25.4 26.9 26.2 30.3
Dead 398 – – 2 11 12 17 43 43 38 48 35 32 49 44 24
Mortality* 7.6 – – 0.4 3 3.5 5.4 11.5 11.5 10 17 15.2 13.5 24 34 34.6
*per 100,000 women/year
TABLE 2





in the last 3 years
No examination
>5 years >10 years
IB-1 105 44.7 59 (56.2%) 21 (20%) 2 (1.9%)
IB-2 42 44.1 20 (42.9%) 14 (33.3%) 4 (9.5%)
IIB 91 54.5 31 (34%) 35 (38.4%) 14 (15.4%)
IIIB-IV 14 74 1 (7%) 6 (43%) 6 (43%)
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Data from the Clinic of Obstetrics and Gynaecology in
Motol also show that 44.0% of women diagnosed with in-
vasive cervical cancer had visited a gynaecologist for
colposcopy/cytology within the 3 year, and 60.0% had vis-
ited within the 5 years before being diagnosed with can-
cer (Table 2). These data clearly indicate that the diag-
nostic process is failing a large proportion of the Czech
women who are attending for screening.
Conclusion
Screening cervical carcinoma in the Czech Republic
has been opportunistic since 1966. Despite a very high
frequency of screening visits and a historically wide age
range, the incidence of cervical cancer has not changed in
the last 34 years. The coverage of Czech women by the
screening is not known exactly but it is estimated to be
50% at the most. Further, for those who are attending for
screening, the high percentage of women with IB-2 cervi-
cal cancer, who have been examined by cytology and
colposcopy within the last 3 years, suggests that the
screening and diagnostic processes are inadequate.
It has been clearly established that organised cervical
cancer screening programmes with quality control at all
levels of the process offer the most cost-effective protec-
tion against cervical cancer and can prevent up to 80% of
cervical cancers in the populations they serve. Because of
these facts, the Council of the European Union, the Eu-
ropean Commission, the International Agency for Re-
search on Cancer, the European Parliament Cervical
Cancer Interest Group, together with a number of other
prestigious organisations has recommended that all Eu-
ropean countries should implement organised cervical
cancer screening programmes. The data noted above
clearly indicate that the Czech Republic is not fulfilling
its obligations to the women of this country and the im-
plantation of these programmes must now be a priority.
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PROBIR RAKA VRATA MATERNICE U REPUBLICI ^E[KOJ
S A @ E T A K
Citolo{ka dijagnoza atipi~nih stanica vrata maternice metodom Papanicolaou-a je uvedena ve} 1947. g. u Republici
^e{koj. Prvi podaci o pojavnosti raka vrata maternice u Republici ^e{koj su dostupni od 1960. g. kada je stopa po-
javnosti iznosila 32,3 slu~aja/105 `ena. 1966. g. ^e{ko nacionalno zdravstveno pravo je donijelo jamstvo `enama da }e
godi{nji preventivni ginekolo{ki pregled uklju~uju}i probir raka vrata maternice biti pokriven obaveznim zdravstvenim
osiguranjem. Unato~ visokom odazivu na probir i ~injenici da su sve `ene podobne, stopa pojavnosti raka vrata ma-
ternice se nije mijenjala u posljednje 34 godine. Razlozi za to uklju~uju nisku pokrivenost `ena u Republici ^e{koj
(najvi{e 50%), ~injenicu da niti jedan citolo{ki laboratorij nije ovla{ten za probir, nepostojanje nacionalnih registara za
bilo koji aspekt programa te nepostojanje na~ina procjene procesa probira. Kao rezultat se mo`e o~ekivati da }e ve}ina
aktivnosti probira raka vrata maternice biti neu~inkovita te je uvo|enje organiziranog programa probira s kontrolom
kvalitete, zajedno s preporukama mnogih Europskih institucija, hitno potrebno kako bi se `enama u Republici ^e{koj
osigurala pravilna za{tita od ove bolesti te da oskudni izvori zdravstvenog osiguranja budu upotrijebljeni na naju~in-
kovitiji na~in.
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